Randomized Placebo-Controlled Trial Assessing a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Plasma Asymmetric Dimethylarginine Concentration in Mild to Moderate CKD

P.W.B. Nanayakkara, J.C. Kiefte-de Jong, P.M. ter Wee, C.D.A. Stehouwer, F.J. van Ittersum, M.R. Olthof, T. Teerlink, J. Twisk, C. van Guldener, Y.M. Smulders

Research output: Contribution to journalArticleAcademicpeer-review

40 Citations (Scopus)

Abstract

Background: Chronic kidney disease (CKD) is associated with an increased incidence of cardiovascular disease (CVD). The Anti-oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study showed that a multistep treatment strategy improved carotid intima-media thickness, endothelial function, and microalbuminuria in patients with stages 2 to 4 CKD. Increased plasma concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, have been linked to greater CVD risk in patients with CKD. The aim of this study is to assess effects of the multistep intervention on plasma ADMA concentrations in the ATIC Study. Study Design: Secondary analysis of a randomized double-blind placebo-controlled trial. Setting & Participants: 93 patients with creatinine clearance of 15 to 70 mL/min/1.73 m
Original languageEnglish
Pages (from-to)41-50
JournalAmerican Journal of Kidney Diseases
Volume53
Issue number1
DOIs
Publication statusPublished - 2009

Cite this